NEW YORK (GenomeWeb News) – DxS said today that it plans to double the size of its Manchester, UK, manufacturing facility and to hire an undisclosed amount of new staff “over the coming months.”
 
The company said that the increase in capacity is the result of growing demand for its TheraScreen K-RAS assay, which determines patients’ K-RAS mutation status.
 
DxS said that the assay is the “preferred method” for K-RAS mutation screening for Amgen's Vectibix colorectal cancer therapy.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.